# HanchorBio Inc. 漢康生技股份有限公司

> HanchorBio is a clinical-stage biotechnology company building next-generation cancer and autoimmune therapies on its proprietary Fc-Based Designer Biologics (FBDB) platform. Founded in 2020 by Henlius co-founder Scott Liu, the company engineers multi-target Fc fusion proteins designed to reach tumors that resist conventional PD-1/PD-L1 checkpoint drugs. Its lead candidate, HCB101, is an affinity-optimized SIRPalpha-Fc fusion protein targeting the CD47-SIRPalpha 'don't eat me' pathway, engineered to spare red blood cells and avoid the anemia that sank earlier anti-CD47 programs. With operations spanning Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is advancing a pipeline across solid and hematologic cancers and autoimmune disease.

- **Founded:** 2020
- **Headquarters:** Taipei, Taiwan (with offices in Shanghai and the San Francisco Bay Area)
- **Founders:** Scott Liu (Founder, Chairman & CEO (co-founder of Shanghai Henlius Biotech))
- **Team size:** ~43 employees
- **Products:** FBDB Platform (Fc-Based Designer Biologics), HCB101, HCB301, HCB303, HCB206
- **Notable:** Lead candidate HCB101 advanced into multi-regional Phase 1/2 trials with clearances from the FDA, China's NMPA, and Taiwan's TFDA, Reported two confirmed partial responses (head and neck squamous cell carcinoma and lymphoma) plus durable disease control in Phase 1, with no dose-limiting toxicities up to 24 mg/kg, Received FDA Orphan Drug Designation for HCB101 in gastric cancer

## Products & services

- **FBDB Platform (Fc-Based Designer Biologics)** — Proprietary protein-engineering platform that uses an IgG Fc backbone to build biologics hitting multiple pathways at once, aimed at improving efficacy against tumors resistant to anti-PD-1/PD-L1 therapy.
- **HCB101** — Lead candidate: an affinity-optimized SIRPalpha-IgG4 Fc fusion protein targeting the CD47-SIRPalpha 'don't eat me' pathway. Engineered for ~100-fold improved CD47-binding affinity and over 1,000-fold greater signal-blocking potency versus earlier constructs, with low red blood cell binding to avoid anemia. In multi-regional Phase 1/2 trials for solid and hematologic tumors (NCT05892718).
- **HCB301** — Pipeline immunotherapy candidate built on the FBDB platform, advancing toward first-in-human clinical evaluation.
- **HCB303** — Earlier-stage FBDB-derived biologic candidate in the oncology pipeline.
- **HCB206** — FBDB-based program expanding HanchorBio's reach into autoimmune diseases.

## Achievements

- Lead candidate HCB101 advanced into multi-regional Phase 1/2 trials with clearances from the FDA, China's NMPA, and Taiwan's TFDA
- Reported two confirmed partial responses (head and neck squamous cell carcinoma and lymphoma) plus durable disease control in Phase 1, with no dose-limiting toxicities up to 24 mg/kg
- Received FDA Orphan Drug Designation for HCB101 in gastric cancer
- Signed a licensing deal with Henlius worth up to $202M for HCB101 across Greater China, Southeast Asia, and MENA
- HCB101 preclinical and clinical data accepted for publication in the Journal of Hematology & Oncology
- Won the Merck Biotech Grant Grand Prize and Taiwan's National Innovation Award (Enterprise Innovation Award) in 2024
- Founder & CEO Scott Liu recognized among '30 Best CEOs of the Year 2024'
- Listed on Taiwan's Innovation Board

## Latest updates

- **2025-07** — Signed a licensing agreement with Henlius worth up to $202M for HCB101 across Greater China, Southeast Asia, and MENA.
- **2025-10** — Presented Phase 1 HCB101 clinical results at FACO 2025 in Shanghai, showing a cytopenia-sparing safety profile, >90% CD47 receptor occupancy at >=1.28 mg/kg, and early antitumor activity.
- **2025-11** — Appointed Dr. Alvin Luk as Group President & Chief Medical Officer (and CEO, USA); presented first-in-human HCB101 monotherapy data in relapsed/refractory non-Hodgkin lymphoma at ASH 2025.
- **2026-06** — Continued pipeline progress including HCB301 first-in-human updates and HCB101 combination data presented at oncology and immunology congresses.

## Links

- Website: https://hanchorbio.com
- LinkedIn: https://www.linkedin.com/company/hanchorbio-inc
- YouTube: https://www.youtube.com/@hanchorbio

---

Profile page: https://yespress.io/hanchorbio-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-15